Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

By GlobeNewswire

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:

Guggenheim 3rd Annual Healthcare Innovation Conference, Boston

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time – Tuesday, Nov. 10, 2026 at 11:30am ET

Jefferies Global Healthcare Conference, London

  • Format – Presentation and one-on-one investor meetings
  • Date and Time – Monday, Nov. 16, 2026 at 4:30pm GMT / 11:30am ET

UBS Global Biopharma Conference 2026, London

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time – Tuesday, Nov. 17, 2026 at 11:40am GMT / 6:40am ET

Piper Sandler 38th Annual Healthcare Conference, New York

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time – Tuesday, Dec. 1, 2026 at 1:30pm ET

9th Annual Evercore Healthcare Conference, Miami

  • Format – Fireside chat and one-on-one investor meetings
  • Date and Time – Wednesday, Dec. 2, 2026 at 12:30pm ET

Live webcasts of the presentation and fireside chats will be available on the investor section of the First Tracks website at https://ir.firsttracksbio.com/news-events/events. Replays of the webcasts will be available for at least 30 days following the events.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.

Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
investors@firsttracksbio.com


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.